A Phase II clinical trial investigating the efficacy of the psychedelic compound lysergic acid diethylamide (LSD) in combination with psychotherapy for the treatment of anxiety has reported positive ...
Two later-stage trials investigating LSD for treating anxiety are due to conclude in 2026, which could lead to the drug being ...
LSD is an extremely potent, long-lasting psychedelic drug: A dose of just 100 micrograms is enough to send someone on a hallucinatory trip that can last a whole day. Now, scientists report that the ...
diethylamide (LSD) is a type of drug that is regulated in various countries, including Japan, but regular doses of very small doses increase concentration and productivity, leading to depression. It ...
Taking a drug such as Lysergic Acid Diethylamide (LSD) has been known to cause hallucinations or a heightened sense of self. Modern brain scans have recently revealed a visual showing the effects of ...
Data to Support MindMed's Project Lucy in Preparing Phase 2b Trial for Anxiety Disorders NEW YORK, Nov. 2, 2020 /CNW/ -- MindMed (NEO: MMED, OTCQB: MMEDF), the leading psychedelic medicine biotech ...
Just weeks after a double-blind, placebo-controlled trial found psilocybin microdosing to be no different to placebo, another study has been published that found LSD microdoses have no effect on mood ...
Researchers are pouring water on the belief that microdosing LSD actually does anything (at least, anything positive) for those who do it. According to The Guardian, the practice became a Silicon ...
Previous studies have shown that the hallucinogenic effects of LSD are mediated to a large extent by the signaling pathway involving the β-arrestin-2 protein. Thus, it is possible that compounds that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback